Cytek Biosciences (Cytek Biosciences) Interest Expense : $-2.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cytek Biosciences's interest expense for the three months ended in Dec. 2023 was $ -0.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cytek Biosciences's Operating Income for the three months ended in Dec. 2023 was $ -0.1 Mil. Cytek Biosciences's Interest Expense for the three months ended in Dec. 2023 was $ -0.4 Mil. Cytek Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cytek Biosciences Interest Expense Historical Data

The historical data trend for Cytek Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences Interest Expense Chart

Cytek Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.33

-1.74

-2.57

-2.07

Cytek Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial												-0.69	-0.67	-0.41	-0.60	-0.39

Cytek Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.1 Mil.

Cytek Biosciences (NAS:CTKB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cytek Biosciences's Interest Expense for the three months ended in Dec. 2023 was $-0.4 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-0.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $11.1 Mil.

Cytek Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Cytek Biosciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cytek Biosciences (Cytek Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

8EQ:Germany

Address

47215 Lakeview Boulevard, Fremont, CA, USA, 94538

Website

https://www.cytekbio.com

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.

Executives

Patrick Jeanmonod	officer: Chief Financial Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Ming Yan	director, officer: Chief Technology Officer	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang	director, officer: President and CEO	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque	officer: SVP, Global Sales and Services	47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams	officer: Chief Operating Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison	director
Deborah J Neff	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland	officer: Chief Commercial Officer	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper	director	C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron	director	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng	director	SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116